skip to Main Content

Cancer Services

Lung Cancer

Please see below all current lung cancer clinical trials of the Central Coast Cancer Centre.

Name: Relativity CA 224-104

A study to evaluate the safety and effectiveness of combining trial anticancer drugs with chemotherapy, in people with non-small cell lung cancer.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Temporarily on hold
Condition: Lung Cancer
External page link More information about Relativity CA 224-104

Name: DREAM3R

A phase 3 Randomised trial DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma.

Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Lung Cancer- Mesothelioma
External page link More information about DREAM3R

Name: CA209-73L

A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Principal Investigator: Dr Matthew Chan
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Lung Cancer
External page link More information about CA209-73L

Name: SGNLV-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic solid tumours.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Lung Cancer
External page link More information about SGNLV-005

Name: PACIFIC 9 

Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.

Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Open
Condition: Lung Cancer
External page link More information about PACIFIC 9

Name: LAGOON

A Randomised, Multicentre, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) In Relapsed Small Cell Lung Cancer (SCLC) patients. LAGOON.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Open
Condition: Lung Cancer
External page link More information about LAGOON

Name: HLX10-020-SCLC302

A randomised, double-blind, International Multicentre, Phase III Study to evaluate the Efficacy and safety of HLX10 in combination with Chemotherapy and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer.

Principal Investigator: Dr Matthew Chan
Study Coordinator: Cassandra Rubio
Status: Open
Condition: Small Cell Lung Cancer
External page link More information about HLX10-020-SCLC302

More information

For more information about medical oncology clinical trials please contact the Nurse Unit Manager on 02 4320 9890 or see:

Internal page Research and Clinical Trials

Back To Top